Declining CRO Business Backlog and Risks to Project Build-Up
First written in FY2019-Q2. 8 of 19 entries say "Mitigated", first in FY2021-Q3. Latest entry: 2026-05-07.
Intage Holdings moved to the "Worse" side of this theme in 2019.
0 other companies' latest entry also says "Mitigated".
- 2026-05-07MitigatedFinancial Results PresentationSuggests it is closing out
「The CRO business was transferred to Alfresa Holdings Corporation on 2 September 2024.」
CRO revenue was zero by product, with the note stating that the business had already been transferred. This indicates that the previous risks relating to the CRO business's order backlog and pipeline are moving toward resolution. - FY2025MitigatedAnnual report
「Revenue declined due to the sale of the CRO business by 株式会社インテージヘルスケア, but profitability improved substantially.」
Regarding the previous risks concerning CRO business orders and profitability, the company stated that overall healthcare business profitability improved substantially after the business transfer in September 2024, indicating that the risks had been reduced. - FY2024MitigatedAnnual report
「株式会社インテージヘルスケア has decided to refocus on its strength of "creating value from data" and concentrate management resources on its marketing research and data science businesses to address these issues. Accordingly, it decided to transfer its CRO business, which supports the safety and efficacy of prescription drugs and other products, to アルフレッサ ホールディングス株式会社.」
Amid continued weakness in CRO business sales, the company transferred the shares of the newly established company to アルフレッサ ホールディングス on 2 September 2024, reducing risk by exiting the CRO business. - FY2024-Q3RestatedAnnual report
「CROs (contract research organizations) have remained below the previous year's level, but the company is working to generate new projects through participation in industry conferences and sales activities using its website.」
The CRO business has remained below the previous year's level, while the company is pursuing new project generation through participation in industry conferences and sales activities using its website. - FY2024-Q2RestatedAnnual report
「CROs (contract research organizations) have remained below the previous year's level due to the decline following the completion of large projects.」
The CRO business has remained below the previous year's level due to the decline following the completion of large projects, and weakness in sales has continued. - FY2024-Q1RestatedAnnual report
「CROs (contract research organizations) have remained below the previous year's level due to the decline following the completion of large projects.」
The CRO business has remained below the previous year's level due to the decline following the completion of large projects, and weakness in sales has continued. - FY2023-Q3CRO sales below the previous year alongside improved profitabilityAnnual report
「CRO was slightly below the previous year's level, but profitability improved as a result of improvement across the business.」
The CRO business was slightly below the previous year's level, while profitability improved as a result of improvement across the business. Weakness in sales and improved profitability coexisted. - FY2023-Q1MitigatedAnnual report
「The CRO business exceeded the previous year's level as a result of fundamental improvement across the business, and profitability also improved.」
The disclosure states that the CRO business exceeded the previous year's level as a result of fundamental improvement, with profitability also improving, indicating progress in addressing the previous decline in profitability. - FY2022MitigatedAnnual report
「In CRO post-marketing studies, sales were below the previous fiscal year's level, but profitability improved as a result of fundamental improvement initiatives across the business.」
The disclosure states that sales from CRO post-marketing studies were below the previous fiscal year's level, while profitability improved as a result of fundamental improvement, indicating progress in addressing the previous decline in profitability. - FY2022-Q2MitigatedAnnual report
「Profit increased due to higher sales and a reduction in unprofitable projects.」
In the Healthcare business, the reduction in unprofitable projects was identified as a factor contributing to higher profit, and progress was reported in addressing the decline in profitability previously seen in CRO and other operations. - FY2022-Q1MitigatedAnnual report
「At 株式会社インテージヘルスケア, the core research business maintained a level comparable to the previous year, while profitability in CRO post-marketing studies is also improving as a result of fundamental improvement initiatives across the business.」
The disclosure states that profitability in CRO post-marketing studies is beginning to improve as a result of fundamental improvement across the business, indicating progress in addressing the previous decline in profitability. - FY2021RestatedAnnual report
「Meanwhile, profitability in CRO post-marketing studies has declined due to the smaller scale of projects and the occurrence of unprofitable projects, and the Company is working to improve it.」
In CRO post-marketing studies, declining profitability due to smaller projects and unprofitable projects continues, while the Company continues its improvement initiatives. - FY2021-Q3MitigatedAnnual report
「Meanwhile, profitability in CRO post-marketing studies had declined due to the smaller scale of projects and the occurrence of unprofitable projects, but the results of initiatives to improve profitability are beginning to emerge.」
The disclosure states that the effects of improvement measures are beginning to emerge in CRO post-marketing studies, where profitability had declined due to smaller projects and unprofitable projects, indicating initial signs of a reduction in the risk. - FY2021-Q2RestatedAnnual report
「Meanwhile, although signs of recovery have emerged in CRO post-marketing studies, sales continue to decline due to the impact of stagnation in pharmaceutical companies' MR activities resulting from COVID-19 and the smaller scale of projects.」
Although signs of recovery have emerged in CRO post-marketing studies, sales continue to decline due to stagnation in MR activities and the smaller scale of projects. - FY2021-Q1WorsenedAnnual report
「Meanwhile, sales from CRO post-marketing studies declined due to stagnation in pharmaceutical companies' MR activities resulting from the spread of COVID-19.」
For CRO post-marketing studies, the decline in sales caused by stagnation in pharmaceutical companies' MR activities has emerged in addition to the previously identified reduction in project size. - FY2020-Q3RestatedAnnual report
「At 株式会社インテージヘルスケア, custom research relating to prescription pharmaceuticals and medical devices, including web surveys of physicians, and panel research relating to over-the-counter drugs have remained solid. However, sales from CRO post-marketing studies are trending downward due to the smaller scale of projects. The Company will continue working to win projects for safety management services, clinical development services, and other areas.」
The Company continues to pursue its policy of building up orders by winning projects for safety management services, clinical development services, and other areas, amid a continuing decline in sales from CRO post-marketing studies. - FY2020-Q1RestatedAnnual report
「In this business, custom research relating to prescription pharmaceuticals and medical devices and panel research relating to over-the-counter drugs at the newly established 株式会社インテージヘルスケア have remained solid. However, sales are trending downward in CRO post-marketing studies due to the smaller scale of commissioned projects. In addition to increasing sales by expanding the number of projects, the Company will continue working to win projects for safety management services and other areas.」
Sales from CRO post-marketing studies are trending downward as commissioned projects have become smaller. The Company continues to work on increasing the number of projects and winning safety management service projects. - FY2019-Q4WorsenedAnnual report
「In this business, custom research relating to prescription pharmaceuticals and panel research relating to over-the-counter drugs at the newly established 株式会社インテージヘルスケア have remained solid. However, sales are trending downward in CRO post-marketing studies due to the smaller scale of commissioned projects. In addition to increasing sales by expanding the number of projects, the Company will continue working to win projects for safety management services and other areas.」
Sales from CRO post-marketing studies are trending downward as commissioned projects have become smaller. The Company continues to work on increasing the number of projects and winning safety management service projects. The risk relating to building up orders is continuing and worsening. - FY2019-Q2MaterialisedAnnual report
「At 株式会社アスクレップ, in light of the decline in the backlog of orders at the end of the previous fiscal year for post-marketing studies, the main CRO business, the Company is working to win projects, including safety management services, to build up orders during the current fiscal year.」
The backlog of CRO orders at the end of the previous fiscal year declined, and the Company is building up orders by winning projects for safety management services and other areas.